Related Experiment Video
Updated: Apr 25, 2026
09:02
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
11.4K
Palliative treatment for symptomatic malignant pericardial effusion†
Guled M Jama1, Marco Scarci2, Jack Bowden3
1Department of Medicine, University of Cambridge, Cambridge Institute for Medical Research (CIMR), Wellcome Trust/MRC Building, Cambridge, UK Papworth Hospital NHS Foundation Trust, Cambridge, UK gmj30@cam.ac.uk.
Interactive Cardiovascular and Thoracic Surgery
|August 22, 2014
Summary
Surgical pericardial effusion drainage offers superior symptom relief and lower recurrence rates compared to non-surgical methods in cancer patients. Further randomized trials are needed to confirm these findings and address selection bias.
Area of Science:
- Cardiology
- Oncology
- Surgical Oncology
Background:
- Malignant pericardial effusion management lacks a consensus on optimal therapy.
- Pericardial effusion in cancer patients presents significant clinical challenges.
Purpose of the Study:
- To evaluate the clinical effectiveness of surgical versus non-surgical treatments for malignant pericardial effusion.
- To synthesize existing evidence on intervention success, recurrence, and complications.
Main Methods:
- A formal literature search identified studies on pericardial effusion treatment in cancer patients.
- Quantitative synthesis of data from 59 selected articles involving 1399 patients.
- Data extraction focused on intervention type, success rates, recurrence, and complications.
Main Results:
- Surgical approaches (19 studies) showed high success rates (93.3-100%) with lower complication rates (4.5-10.3%).
- Non-surgical modalities (40 studies) had variable success rates (55.1-90.4%) but higher complication rates (5.9-32%).
- Surgical drainage demonstrated superiority in symptom relief, effusion recurrence, and morbidity.
Conclusions:
- Surgical pericardial effusion drainage appears more effective than non-surgical options.
- Lack of randomized controlled trials limits definitive conclusions due to potential selection bias.
- High-quality, controlled trials are a priority for establishing definitive treatment guidelines.
Related Concept Videos
01:17Pericarditis III: Medical Management
583
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
583
01:29Cardiomyopathy V: Interprofessional Care
746
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
746
01:25Pericarditis IV: Nursing Management
636
Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
636
01:30Cardiomyopathy II: Dilated Cardiomyopathy
785
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
785
01:19Pericarditis II: Clinical Features and Diagnostic Tests
626
Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
626
01:14Myocarditis III: Medical Management
342
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
342